The authors (Waleed F. Khalaf, MD; Meghan E. Caldwell, BS, MSN; and Nishitha Reddy, MD, MSCI) have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Nicole B. Harrold, BS, Manager, Continuing Education and Grants
Ms. Harrold has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Sharaiha RZ, Lebwohl B, Reimers L et al. . Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. Cancer 2012;118:3786–3792.
Murray A, Cuevas EC, Jones DB, Wright DH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol 1995;146:509–519.
Gale J, Simmonds PD, Mead GM et al. . Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000;18:795–803.
Novakovic BJ, Novakovic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep 2006;16:191–195.
Daum S, Ullrich R, Heise W et al. . Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal Non-Hodgkin's Lymphoma. J Clin Oncol 2003;21:2740–2746.
Egan LJ, Walsh SV, Stevens FM et al. . Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995;21:123–129.
Wohrer S, Chott A, Drach J et al. . Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol 2004;15:1680–1683.
Sieniawski M, Angamuthu N, Boyd K et al. . Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664–3670.
Delabie J, Holte H, Vose JM et al. . Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 2011;118:148–155.
Raderer M, Troch M, Kiesewetter B et al. . Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis. Ann Hematol 2012;91:57–61.
Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631–637.
Younes A, Bartlett NL, Leonard JP et al. . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
Pro B, Advani R, Brice P et al. . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–2196.
Zelenetz AD, Abramson JS, Advani RH et al. . NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas. Version 1.2013. Available at: NCCN.org. Accessed January 16, 2013.